// App-Quantinova.ai

OC 50.5 : Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors

Researchers

Presenter

  • J. Windyga

Principal Investigators

  • P. Chowdary

  • J. Mahlangu

Medical Centers

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • The Royal Marsden Hospital, London, United Kingdom

  • Hospital Universitario Regional de Málaga, Malaga, Spain

  • Novo Nordisk A/S, Måløv, Hovedstaden, Denmark

  • University of Witwatersrand, Johannesburg, South Africa

Locations

  • Poland

  • United Kingdom

  • Spain

  • Denmark

  • South Africa

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Evithrom

Outcome

  • N/A

Study Design

  • Open Label

  • Multiple Ascending Dose

  • Cohort

Phase

  • II

Study Id's

  • NCT04204408

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved